A G Waks1, O Cohen2, B Kochupurakkal3, D Kim2, C E Dunn3, J Buendia Buendia2, S Wander4, K Helvie5, M R Lloyd6, L Marini5, M E Hughes7, S S Freeman8, S P Ivy9, J Geradts10, S Isakoff11, P LoRusso12, V A Adalsteinsson8, S M Tolaney13, U Matulonis13, I E Krop13, A D D'Andrea14, E P Winer13, N U Lin13, G I Shapiro15, N Wagle16. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA. 2. Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA. 3. Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA. 4. Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA. 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; University of Massachusetts Medical School, Worcester, USA. 7. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 8. Broad Institute of MIT and Harvard, Cambridge, USA. 9. Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA. 10. City of Hope Comprehensive Cancer Center, Duarte, USA. 11. Harvard Medical School, Boston, USA; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, USA. 12. Yale Cancer Center, New Haven, USA. 13. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA. 14. Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA. 15. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA. 16. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA. Electronic address: nikhil_wagle@dfci.harvard.edu.
Abstract
BACKGROUND: Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to prevent or overcome treatment failure. PATIENTS AND METHODS: We obtained tumor biopsies from metastatic breast cancer patients with BRCA1/2 deficiency before and after acquired resistance to PARPi or platinum chemotherapy. Whole exome sequencing was carried out on each tumor, germline DNA, and circulating tumor DNA. Tumors underwent RNA sequencing, and immunohistochemical staining for RAD51 foci on tumor sections was carried out for functional assessment of intact homologous recombination (HR). RESULTS: Pre- and post-resistance tumor samples were sequenced from eight patients (four with BRCA1 and four with BRCA2 mutation; four treated with PARPi and four with platinum). Following disease progression on DNA-damaging therapy, four patients (50%) acquired at least one somatic reversion alteration likely to result in functional BRCA1/2 protein detected by tumor or circulating tumor DNA sequencing. Two patients with germline BRCA1 deficiency acquired genomic alterations anticipated to restore HR through increased DNA end resection: loss of TP53BP1 in one patient and amplification of MRE11A in another. RAD51 foci were acquired post-resistance in all patients with genomic reversion, consistent with reconstitution of HR. All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy. CONCLUSIONS: Genomic reversion in BRCA1/2 was the most commonly observed mechanism of resistance, occurring in four of eight patients. Novel sequence alterations leading to increased DNA end resection were seen in two patients, and may be targetable for therapeutic benefit. The presence of RAD51 foci by immunohistochemistry was consistent with BRCA1/2 protein functional status from genomic data and predicted response to later DNA-damaging therapy, supporting RAD51 focus formation as a clinically useful biomarker.
BACKGROUND: Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to prevent or overcome treatment failure. PATIENTS AND METHODS: We obtained tumor biopsies from metastatic breast cancerpatients with BRCA1/2 deficiency before and after acquired resistance to PARPi or platinum chemotherapy. Whole exome sequencing was carried out on each tumor, germline DNA, and circulating tumor DNA. Tumors underwent RNA sequencing, and immunohistochemical staining for RAD51 foci on tumor sections was carried out for functional assessment of intact homologous recombination (HR). RESULTS: Pre- and post-resistance tumor samples were sequenced from eight patients (four with BRCA1 and four with BRCA2 mutation; four treated with PARPi and four with platinum). Following disease progression on DNA-damaging therapy, four patients (50%) acquired at least one somatic reversion alteration likely to result in functional BRCA1/2 protein detected by tumor or circulating tumor DNA sequencing. Two patients with germline BRCA1 deficiency acquired genomic alterations anticipated to restore HR through increased DNA end resection: loss of TP53BP1 in one patient and amplification of MRE11A in another. RAD51 foci were acquired post-resistance in all patients with genomic reversion, consistent with reconstitution of HR. All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy. CONCLUSIONS: Genomic reversion in BRCA1/2 was the most commonly observed mechanism of resistance, occurring in four of eight patients. Novel sequence alterations leading to increased DNA end resection were seen in two patients, and may be targetable for therapeutic benefit. The presence of RAD51 foci by immunohistochemistry was consistent with BRCA1/2 protein functional status from genomic data and predicted response to later DNA-damaging therapy, supporting RAD51 focus formation as a clinically useful biomarker.
Authors: Sarah J Hill; Brennan Decker; Emma A Roberts; Neil S Horowitz; Michael G Muto; Michael J Worley; Colleen M Feltmate; Marisa R Nucci; Elizabeth M Swisher; Huy Nguyen; Chunyu Yang; Ryuji Morizane; Bose S Kochupurakkal; Khanh T Do; Panagiotis A Konstantinopoulos; Joyce F Liu; Joseph V Bonventre; Ursula A Matulonis; Geoffrey I Shapiro; Ross S Berkowitz; Christopher P Crum; Alan D D'Andrea Journal: Cancer Discov Date: 2018-09-13 Impact factor: 39.397
Authors: Kalindi Parmar; Bose S Kochupurakkal; Jean-Bernard Lazaro; Zhigang C Wang; Sangeetha Palakurthi; Paul T Kirschmeier; Chunyu Yang; Larissa A Sambel; Anniina Färkkilä; Elizaveta Reznichenko; Hunter D Reavis; Connor E Dunn; Lee Zou; Khanh T Do; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Joyce F Liu; Alan D D'Andrea; Geoffrey I Shapiro Journal: Clin Cancer Res Date: 2019-08-13 Impact factor: 12.531
Authors: Andrew Tutt; Holly Tovey; Maggie Chon U Cheang; Sarah Kernaghan; Lucy Kilburn; Patrycja Gazinska; Julie Owen; Jacinta Abraham; Sophie Barrett; Peter Barrett-Lee; Robert Brown; Stephen Chan; Mitchell Dowsett; James M Flanagan; Lisa Fox; Anita Grigoriadis; Alexander Gutin; Catherine Harper-Wynne; Matthew Q Hatton; Katherine A Hoadley; Jyoti Parikh; Peter Parker; Charles M Perou; Rebecca Roylance; Vandna Shah; Adam Shaw; Ian E Smith; Kirsten M Timms; Andrew M Wardley; Gregory Wilson; Cheryl Gillett; Jerry S Lanchbury; Alan Ashworth; Nazneen Rahman; Mark Harries; Paul Ellis; Sarah E Pinder; Judith M Bliss Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440
Authors: Olga Kondrashova; Minh Nguyen; Kristy Shield-Artin; Anna V Tinker; Nelson N H Teng; Maria I Harrell; Michael J Kuiper; Gwo-Yaw Ho; Holly Barker; Maria Jasin; Rohit Prakash; Elizabeth M Kass; Meghan R Sullivan; Gregory J Brunette; Kara A Bernstein; Robert L Coleman; Anne Floquet; Michael Friedlander; Ganessan Kichenadasse; David M O'Malley; Amit Oza; James Sun; Liliane Robillard; Lara Maloney; David Bowtell; Heidi Giordano; Matthew J Wakefield; Scott H Kaufmann; Andrew D Simmons; Thomas C Harding; Mitch Raponi; Iain A McNeish; Elizabeth M Swisher; Kevin K Lin; Clare L Scott Journal: Cancer Discov Date: 2017-06-06 Impact factor: 39.397
Authors: Samuel W Brady; Jasmine A McQuerry; Yi Qiao; Stephen R Piccolo; Gajendra Shrestha; David F Jenkins; Ryan M Layer; Brent S Pedersen; Ryan H Miller; Amanda Esch; Sara R Selitsky; Joel S Parker; Layla A Anderson; Brian K Dalley; Rachel E Factor; Chakravarthy B Reddy; Jonathan P Boltax; Dean Y Li; Philip J Moos; Joe W Gray; Laura M Heiser; Saundra S Buys; Adam L Cohen; W Evan Johnson; Aaron R Quinlan; Gabor Marth; Theresa L Werner; Andrea H Bild Journal: Nat Commun Date: 2017-11-01 Impact factor: 14.919
Authors: Yifan Wang; Andrea J Bernhardy; Cristina Cruz; John J Krais; Joseph Nacson; Emmanuelle Nicolas; Suraj Peri; Hanneke van der Gulden; Ingrid van der Heijden; Shane W O'Brien; Yong Zhang; Maribel I Harrell; Shawn F Johnson; Francisco J Candido Dos Reis; Paul D P Pharoah; Beth Karlan; Charlie Gourley; Diether Lambrechts; Georgia Chenevix-Trench; Håkan Olsson; Javier J Benitez; Mark H Greene; Martin Gore; Robert Nussbaum; Siegal Sadetzki; Simon A Gayther; Susanne K Kjaer; Alan D D'Andrea; Geoffrey I Shapiro; David L Wiest; Denise C Connolly; Mary B Daly; Elizabeth M Swisher; Peter Bouwman; Jos Jonkers; Judith Balmaña; Violeta Serra; Neil Johnson Journal: Cancer Res Date: 2016-05-01 Impact factor: 12.701
Authors: C Cruz; M Castroviejo-Bermejo; S Gutiérrez-Enríquez; A Llop-Guevara; Y H Ibrahim; A Gris-Oliver; S Bonache; B Morancho; A Bruna; O M Rueda; Z Lai; U M Polanska; G N Jones; P Kristel; L de Bustos; M Guzman; O Rodríguez; J Grueso; G Montalban; G Caratú; F Mancuso; R Fasani; J Jiménez; W J Howat; B Dougherty; A Vivancos; P Nuciforo; X Serres-Créixams; I T Rubio; A Oaknin; E Cadogan; J C Barrett; C Caldas; J Baselga; C Saura; J Cortés; J Arribas; J Jonkers; O Díez; M J O'Connor; J Balmaña; V Serra Journal: Ann Oncol Date: 2018-05-01 Impact factor: 32.976
Authors: Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang Journal: Cell Rep Date: 2018-04-03 Impact factor: 9.423
Authors: Viktor A Adalsteinsson; Gavin Ha; Samuel S Freeman; Atish D Choudhury; Daniel G Stover; Heather A Parsons; Gregory Gydush; Sarah C Reed; Denisse Rotem; Justin Rhoades; Denis Loginov; Dimitri Livitz; Daniel Rosebrock; Ignaty Leshchiner; Jaegil Kim; Chip Stewart; Mara Rosenberg; Joshua M Francis; Cheng-Zhong Zhang; Ofir Cohen; Coyin Oh; Huiming Ding; Paz Polak; Max Lloyd; Sairah Mahmud; Karla Helvie; Margaret S Merrill; Rebecca A Santiago; Edward P O'Connor; Seong H Jeong; Rachel Leeson; Rachel M Barry; Joseph F Kramkowski; Zhenwei Zhang; Laura Polacek; Jens G Lohr; Molly Schleicher; Emily Lipscomb; Andrea Saltzman; Nelly M Oliver; Lori Marini; Adrienne G Waks; Lauren C Harshman; Sara M Tolaney; Eliezer M Van Allen; Eric P Winer; Nancy U Lin; Mari Nakabayashi; Mary-Ellen Taplin; Cory M Johannessen; Levi A Garraway; Todd R Golub; Jesse S Boehm; Nikhil Wagle; Gad Getz; J Christopher Love; Matthew Meyerson Journal: Nat Commun Date: 2017-11-06 Impact factor: 14.919
Authors: Anniina Färkkilä; Alfredo Rodríguez; Jaana Oikkonen; Doga C Gulhan; Huy Nguyen; Julieta Domínguez; Sandra Ramos; Caitlin E Mills; Fernando Pérez-Villatoro; Jean-Bernard Lazaro; Jia Zhou; Connor S Clairmont; Lisa A Moreau; Peter J Park; Peter K Sorger; Sampsa Hautaniemi; Sara Frias; Alan D D'Andrea Journal: Cancer Res Date: 2021-01-29 Impact factor: 12.701
Authors: Xuan Liu; Zhongqi Ge; Fei Yang; Alejandro Contreras; Sanghoon Lee; Jason B White; Yiling Lu; Marilyne Labrie; Banu K Arun; Stacy L Moulder; Gordon B Mills; Helen Piwnica-Worms; Jennifer K Litton; Jeffrey T Chang Journal: NPJ Breast Cancer Date: 2022-05-10
Authors: Zheqi Li; Olivia McGinn; Yang Wu; Amir Bahreini; Nolan M Priedigkeit; Kai Ding; Sayali Onkar; Caleb Lampenfeld; Carol A Sartorius; Lori Miller; Margaret Rosenzweig; Ofir Cohen; Nikhil Wagle; Jennifer K Richer; William J Muller; Laki Buluwela; Simak Ali; Tullia C Bruno; Dario A A Vignali; Yusi Fang; Li Zhu; George C Tseng; Jason Gertz; Jennifer M Atkinson; Adrian V Lee; Steffi Oesterreich Journal: Nat Commun Date: 2022-04-19 Impact factor: 17.694